Stating daily or recent moves might obscure the true scale of the strategic failure of ECOR, still laboring under direction set by founders. Stock price is currently -96.56% below historic high. Market size projections for ECOR products based on patient populations are irrelevant red herrings, as the physicians prefer to prescribe drugs as the 1st, 2nd and 3rd courses of treatment.
It seems that the more that management presents at conferences, the greater the understanding of investors about the true value of the company's current business....resulting in declining stock price.
Market Data 
Markets 
AI
